Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

Twice‐weekly carfilzomib (27 mg/m(2)) with lenalidomide‐dexamethasone (KRd) is a standard‐of‐care in relapsed or refractory multiple myeloma (RRMM). This phase 1b study evaluated KRd with once‐weekly carfilzomib in RRMM. Patients received carfilzomib (30‐minute infusion; 56 or 70mg/m(2)) on days 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Biran, Noa, Siegel, David, Berdeja, Jesus G., Raje, Noopur, Cornell, Robert Frank, Alsina, Melissa, Kovacsovics, Tibor, Fang, Belle, Kimball, Amy S., Landgren, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593978/
https://www.ncbi.nlm.nih.gov/pubmed/31021005
http://dx.doi.org/10.1002/ajh.25498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593978/
https://www.ncbi.nlm.nih.gov/pubmed/31021005
http://dx.doi.org/10.1002/ajh.25498

Ejemplares similares